Patent SG-11201805784P-A (SG)
Title: Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
Inventor: GREVE JEFFREY
IPC: C07K16/46
Filed: 2017-01-19
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/127514 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: C07K 14/55 (2006.01) C07K 16/46 (2006.01) C07K 14/00 (2006.01) (21) International Application Number: PCT/US2017/014090 (22) International Filing Date: 19 January 2017 (19.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/002,144 20 January 2016 (20.01.2016) US (71) Applicant: DELINIA, INC. [US/US]; 400 Technology Square, 10th Floor, Cambridge, Massachusetts 02139 (US). (72) Inventor: GREVE, Jeffrey; 1066 Park Hills Road, Berke- ley, California 94708 (US). (74) Agents: KRIKELIS, Basil, S. et al.; McCarter & English, LLP, Renaissance Centre, 405 N. King Street, 8th Floor, Published: Wilmington, DE 19801 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIM- MUNE DISEASES PEPTIDE LINKER (57) : This invention provides for a fusion protein between an IL2a13y Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2a[3y form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein. 111111111111011011111111111010111110 III 011101011111H 010111111111110111111 W O 20 17 / 1275 14 Al FIG. 2 X-Fc